Patent intelligence · US
US 7491677
Combinatorial synthesis
Combinatorial synthesis
Patent details — US 7491677
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 17, 2009
- Expiration
- Feb 12, 2029
- Applicant
- BASF CATALYSTS LLC
- Claims
- 40
- CPC classes
- A61P, A61P11/06, A61P17/06, A61P19/02
Quick answer
US 7491677 (Combinatorial synthesis) is held by BASF CATALYSTS LLC. Status: granted. Granted Feb 17, 2009. Expires Feb 12, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BASF CATALYSTS LLC
- Grant date
- Expiration
- Claims
- 40
- CPC classes
- A61P, A61P11/06, A61P17/06, A61P19/02, A61P25/00, A61P29/00
More from BASF CATALYSTS LLC
Related pharmaceutical patents in our USPTO index.
-
US 11806421
Porous-cellulose particles and production method thereof, and cosmetic
granted -
US 11701307
Organic-inorganic composite particles, manufacturing method therefor, and cosmetic
granted -
US 11491212
Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
granted -
US 11401513
Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
granted -
US 11384062
Deuterated (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide
granted -
US 11266724
Modified factor VII polypeptides for subcutaneous administration and on-demand treatment
granted -
US 11203749
Factor VII polypeptides that are modified and uses thereof
granted -
US 11020326
Hollow particles and cosmetic
granted
Frequently asked questions
What is US patent 7491677?
US 7491677 (Combinatorial synthesis) is held by BASF CATALYSTS LLC. Status: granted. Granted Feb 17, 2009. Expires Feb 12, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7491677?
BASF CATALYSTS LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 61 pharmaceutical patents for this assignee.
When does US 7491677 expire?
Our index shows an expiration date of Feb 12, 2029 (3 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.